The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population

被引:51
作者
Caliz, R. [1 ]
del Amo, J. [2 ]
Balsa, A. [3 ]
Blanco, F. [4 ]
Silva, L. [5 ]
Sanmarti, R. [6 ]
Martinez, F. G. [7 ]
Collado, M. D. [1 ]
del Carmen Ramirez, M. [1 ]
Tejedor, D. [2 ]
Artieda, M. [2 ]
Pascual-Salcedo, D. [3 ]
Oreiro, N. [4 ]
Andreu, J. L. [5 ]
Graell, E. [6 ]
Simon, L. [2 ]
Martinez, A. [2 ]
Mulero, J.
机构
[1] Virgen Nieves Univ Hosp, Granada, Spain
[2] Progenika Biopharma SA, Derio, Vizcaya, Spain
[3] La Paz Univ Hosp, Madrid, Spain
[4] Hosp Juan Canalejo, Coruna, Spain
[5] Puerta de Hierro Univ Hosp, Madrid, Spain
[6] Hosp Clin Barcelona, Barcelona, Spain
[7] Univ Hosp, Cordoba, Spain
关键词
LOW-DOSE METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; SINGLE-NUCLEOTIDE POLYMORPHISMS; EFFICACY; FOLATE; THERAPY; DISEASE; ENZYMES; METAANALYSIS; DRUGS;
D O I
10.3109/03009742.2011.617312
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Methotrexate (MTX) is the first-choice drug for the treatment of rheumatoid arthritis (RA) patients. However, 30% of RA patients discontinue therapy within 1 year, usually because of adverse effects. Previous studies have reported conflicting results on the association of polymorphisms in the MTHFR gene with the toxicity of MTX in RA. The aim of this study was to assess the involvement of the C677T and A1298C polymorphisms in the MTHFR gene in the toxicity of MTX in a Spanish RA population. Methods: The study included retrospectively 468 Spanish RA patients treated with MTX. Single nucleotide polymorphism (SNP) genotyping was performed using the oligonucleotide microarray technique. Allele and genotype association analyses with regard to MTX toxicity and a haplotype association test were also performed. Results: Eighty-four out of the 468 patients (18%) had to discontinue therapy due to adverse effects or MTX toxicity. The C677T polymorphism (rs1801133) was associated with increased MTX toxicity [odds ratio (OR) 1.42, 95% confidence interval (CI) 1.01-1.98, p = 0.0428], and the strongest association was shown in the recessive model (OR 1.95, 95% CI 1.08-3.53, p = 0.0246). The A1298C polymorphism (rs1801131) was not associated with increased MTX toxicity (OR 0.94, 95% CI 0.65-1.38, p = 0.761). A borderline significant risk haplotype was found: 677T-1298A (OR 1.40, 95% CI 1.00-1.96, p = 0.0518). Conclusion: These results demonstrate that the C677T polymorphism in the MTHFR gene is associated with MTX toxicity in a Spanish RA population.
引用
收藏
页码:10 / 14
页数:5
相关论文
共 34 条
[21]   Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review [J].
Pincus, T ;
Ferraccioli, G ;
Sokka, T ;
Larsen, A ;
Rau, R ;
Kushner, I ;
Wolfe, F .
RHEUMATOLOGY, 2002, 41 (12) :1346-1356
[22]  
Rath T, 2010, CLIN EXP RHEUMATOL, V28, pS52
[23]   A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmo, Sweden, 1997-2005 [J].
Soderlin, M. K. ;
Lindroth, Y. ;
Turesson, C. ;
Jacobsson, L. T. H. .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2010, 39 (03) :206-211
[24]   Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice [J].
Taniguchi, Atsuo ;
Urano, Wako ;
Tanaka, Eiichi ;
Furihata, Shiorl ;
Kamitsuji, Shigeo ;
Inoue, Eisuke ;
Yamanaka, Mariko ;
Yamanaka, Hisashl ;
Kamatani, Naoyuki .
PHARMACOGENETICS AND GENOMICS, 2007, 17 (06) :383-390
[25]   Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia [J].
Tejedor, D ;
Castillo, S ;
Mozas, P ;
Jiménez, E ;
López, M ;
Tejedor, MT ;
Artieda, M ;
Alonso, R ;
Mata, P ;
Simón, L ;
Martínez, A ;
Pocoví, M .
CLINICAL CHEMISTRY, 2005, 51 (07) :1137-1144
[26]   Biological and clinical implications of the MTHFR C677T polymorphism [J].
Ueland, PM ;
Hustad, S ;
Schneede, J ;
Refsum, H ;
Vollset, SE .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (04) :195-201
[27]   Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses [J].
Urano, W ;
Taniguchi, A ;
Yamanaka, H ;
Tanaka, E ;
Nakajima, H ;
Matsuda, Y ;
Akama, H ;
Kitamura, Y ;
Kamatani, N .
PHARMACOGENETICS, 2002, 12 (03) :183-190
[28]  
van Ede AE, 2001, ARTHRITIS RHEUM, V44, P2525, DOI 10.1002/1529-0131(200111)44:11<2525::AID-ART432>3.0.CO
[29]  
2-B
[30]  
WEINBLATT ME, 1985, J RHEUMATOL, V12, P35